Our mission is to provide you with personalized, high-quality, cost-effective care. Healthcare today can be a cumbersome process and challenging to navigate. Dr. Avalos founded Miami Gastro on the vision that healthcare should be equitable, accessible, and high quality. We accomplish this by taking the time to listen to our patients and if they require additional diagnostic studies, linking them to cost-effective care. Miami Gastro is not affiliated with corporations which allows us the freedom to refer you to cost-effective centers where you can have your imaging or endoscopic procedures.
We are focused on changing healthcare outcomes and we do this by measuring our own. Colon cancer is the 3rd leading cancer in the U.S. and the 2nd leading cause of cancer-related deaths. Colon cancer stems from precursors lesions known as adenomatous polyps. The gastroenterology societies understand that a quality indicator against colon cancer is to measure a proceduralist's adenoma detection rate (ADR). In other words, the proceduralist ability to detect polyps is paramount in the quality of a screening colonoscopy. Joint societies (AGA, ACG, ASGE) in gastroenterology recommend that a proceduralist should accomplish a 25% adenoma detection rate for men and women. In other words, a proceduralist should be able to identify at least 1 adenoma (polyp) in 25 of 100 patients who undergo a screening colonoscopy. Dr. Avalos inputs his outcomes into the GIQuIC Registry (a national database that collects quality indicators in colonoscopy) and has an adenoma detection rate of 53% as compared with the national standard of 25%. As a patient, you should know the adenoma detection rate of your proceduralist. We believe that by reporting our outcomes, we can empower you, the patient.